About the Disease
Tumor- induced Osteomalacia (TIO) is a rare disease that is characterized by tumors causing soft and weakened bones. Lower phosphate levels are caused by the tumors releasing a peptide homeo-like substance known as fibroblast growth factor 23 (FGF23). TIO affects approximately 500-1,000 people in the US. TIO can affect any race, age or gender.
About our Patient Care
Our dedicated Care Team will work with the physician's office and insurance on a patient's behalf so that our patients have more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.
As part of treatment, we provide:
Dedicated Care Team
We provide prescribers and patients with a dedicated care team for each of our disease state programs. This includes a primary pharmacy contact, clinical education, side-effects management, scheduled refill calls, and a direct phone, fax and email address.
Shipping and Coordination of Care
We provide free overnight delivery of medications and necessary medical supplies and manage the coordination of care between prescribers, sites of care, nurses and patients to ensure dispenses and drug delivery align with the date and location of service.
Financial Assistance Coordination
We successfully identify and assist enrolling patients into any and all manufacturer co-pay and foundation support programs in order to minimize a potential financial burden to patients given the high-cost of specialty medications.
24/7/365 Access to a Pharmacist
We provide prescribers and patients access to a pharmacist 24/7/365 to ensure patients are always cared for.
Brand Name | CRYSVITA® (burosumab-twa)
Manufacturer | Ultragenyx
Route of Administration | Subcutaneous injection
Approved Indication | Indicated for the treatment of FGF23 related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.
Self-Administration | No
Product Website | https://www.crysvita.com/tio